Xentria Announces Initial Findings Showing Novel Biologic XTMAB-16’s Potential to Reduce Sarcoidosis Granuloma

June 23, 2022

CHICAGO, JUNE 23, 2022 - Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, presented its first set of data showing its novel biologic, XTMAB-16, has the potential to reduce the formation of sarcoidosis granulomas.

 

Sarcoidosis is a chronic, inflammatory disorder that can affect multiple organs and bodily systems including the skin, eyes, heart, and central nervous system. More than 90% of cases involve the lungs. Symptoms range from asymptomatic to severe — including respiratory problems, blindness, neurological disease, and cardiac death. There is no tumor necrosis factor (TNF)-inhibitor currently FDA approved for the treatment of sarcoidosis.

 

Key findings from the data include:

  • Data derived from ten consecutive patients showed that pretreatment with XTMAB-16 significantly, and dose-dependently, reduces granuloma formation in an in vitro model within the range of 1 μg/ml and 40 μg/ml.
  • XTMAB-16 consistently inhibited in vitro granuloma formation (the key inflammatory feature of sarcoidosis) and related inflammatory molecules, based on an established laboratory model using the actual immune cells of sarcoidosis patients.
  • XTMAB-16 was comparable to the currently accepted first line treatment, corticosteroids, for suppression of in vitro sarcoidosis granuloma formation[1]. The efficacy of XTMAB-16 for reducing disease activity in humans remains to be determined in clinical trials.

 

“These new data are a promising first step in the continued evaluation of XTMAB-16 as a potential therapy for patients with sarcoidosis,” said Thomas Shea, President of Xentria. “The release of this new data reinforces our commitment to the sarcoidosis rare disease community and our mission to develop new breakthrough treatment.”  

 

XTMAB-16 works to limit tissue injury and fibrosis caused by the disease by targeting the cellular signals regulating inflammation, called cytokines. The study evaluated the effect of treatment with XTMAB-16 in an in vitro model using cells taken from patients with lungs and/or lymph nodes affected by active sarcoidosis.

 

“While there are currently medications available to try to manage the symptoms of this rare disease, the available treatments have serious limitations, including limited efficacy and unacceptable side-effects, and there is a pressing need for better treatments,” said investigator Elliott D. Crouser, M.D., Professor of Internal Medicine, Wexner Medical Center, The Ohio State University. “I look forward to working with Xentria to further evaluate XTMAB-16’s potential to reduce disease manifestations and improve the quality of life and care of patients with sarcoidosis.”

 

Data were presented at the American Thoracic Society 2022 International Conference in San Francisco, CA, on May 17, 2022. 

 

XTMAB-16 Attenuates Granuloma Formation in a Human In Vitro Sarcoidosis Model

 

 

About Sarcoidosis Granuloma

Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of non-caseating and non-necrotizing epithelioid granulomas (as opposed to granulomas caused by infections, such as tuberculosis), accompanied by infiltration of mononuclear cells and destruction of microarchitecture.

 

About XTMAB-16

XTMAB-16 is a chimeric human-murine IgG1 anti-TNF monoclonal antibody being developed as a novel biologic product for the treatment of sarcoidosis.

 

About Xentria

Xentria, whose name stems from the word “centrality”, was founded in 2020 and is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of cost-effective and efficacious biologics to address critical unmet need for patients suffering from rare diseases, immunologic disorders and oncological conditions. Headquartered in Chicago, with partners in Israel and China, the company is dedicated to research and development, clinical science, manufacturing, and commercialization, driven to treat the clinical and social burdens of diseases while fostering sustainable growth.

 

To learn more about Xentria visit www.xentria.com.

 

 

Contact

 

FTI Consulting

Jacqui Wilmot, Senior Director

914.435.3863

jacqui.wilmot@fticonsulting.com

 

FTI Consulting

Erin Williams, Director

347.237.2043

erin.williams@fticonsulting.com

 

Xentria, Inc.

Noopur Singh, Senior Manager, Site Engagement and Patient Recruitment

contact@xentria.com


[1] Crouser ED, White P, Caceres EG, et al. A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection. Am J Respir Cell Mol Bio. 2017; 57:487-498.


This website uses cookies

We use cookies to improve your experience on our site. You can read more about our Cookie Policy in our Privacy policy.

Allow cookies Reject cookies